These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8773218)

  • 21. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tardive dyskinesia: prevalence, incidence, and risk factors.
    Kane JM; Woerner M; Lieberman J
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):52S-56S. PubMed ID: 3065365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nicotine exposure and tardive dyskinesia.
    Yassa R; Lal S; Korpassy A; Ally J
    Biol Psychiatry; 1987 Jan; 22(1):67-72. PubMed ID: 3790642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of tardive dyskinesia: results of a cross-sectional study in an outpatient population.
    Morgenstern H; Glazer WM; Gibowski LD; Holmberg S
    J Chronic Dis; 1987; 40(4):319-27. PubMed ID: 2881941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence and risk factors for severe tardive dyskinesia in older patients.
    Caligiuri MP; Lacro JP; Rockwell E; McAdams LA; Jeste DV
    Br J Psychiatry; 1997 Aug; 171():148-53. PubMed ID: 9337951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors in the development of severe forms of tardive dyskinesia.
    Yassa R; Nair NP; Iskander H; Schwartz G
    Am J Psychiatry; 1990 Sep; 147(9):1156-63. PubMed ID: 1974745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.
    Jeste DV; Caligiuri MP; Paulsen JS; Heaton RK; Lacro JP; Harris MJ; Bailey A; Fell RL; McAdams LA
    Arch Gen Psychiatry; 1995 Sep; 52(9):756-65. PubMed ID: 7654127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.
    Sachdev P
    Aust N Z J Psychiatry; 2004 Jun; 38(6):445-9. PubMed ID: 15209837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
    Go CL; Rosales RL; Caraos RJ; Fernandez HH
    Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tardive dyskinesia in elderly psychiatric patients in Singapore.
    Tan CH; Tay LK
    Aust N Z J Psychiatry; 1991 Mar; 25(1):119-22. PubMed ID: 1675562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Focus on lower risk of tardive dyskinesia with atypical antipsychotics.
    Nasrallah HA
    Ann Clin Psychiatry; 2006; 18(1):57-62. PubMed ID: 16517454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong.
    Chiu H; Shum P; Lau J; Lam L; Lee S
    Am J Psychiatry; 1992 Aug; 149(8):1081-5. PubMed ID: 1353316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tardive dyskinesia prevalence rates during a ten-year follow-up.
    Miller CH; Simioni I; Oberbauer H; Schwitzer J; Barnas C; Kulhanek F; Boissel KE; Meise U; Hinterhuber H; Fleischhacker WW
    J Nerv Ment Dis; 1995 Jun; 183(6):404-7. PubMed ID: 7798090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study.
    Paulsen JS; Caligiuri MP; Palmer B; McAdams LA; Jeste DV
    Psychopharmacology (Berl); 1996 Feb; 123(4):307-14. PubMed ID: 8867868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiological aspects of tardive dyskinesia.
    Kane JM; Woerner M; Lieberman J
    Encephale; 1988 Sep; 14 Spec No():191-4. PubMed ID: 3063513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of tardive dyskinesia in a clinic population.
    Fleischhauer J; Kocher R; Hobi V; Gilsdorf U
    Psychopharmacology Suppl; 1985; 2():162-72. PubMed ID: 2860658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A survey of tardive dyskinesia in psychiatric inpatients in Japan.
    Koshino Y; Madokoro S; Ito T; Horie T; Mukai M; Isaki K
    Clin Neuropharmacol; 1992 Feb; 15(1):34-43. PubMed ID: 1349507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.